Dataset Information

Growth hormone for in vitro fertilisation (IVF).

ABSTRACT:

SUBMITTER: Sood A

PROVIDER: S-EPMC8608438 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Growth hormone for in vitro fertilisation (IVF).

Sood Akanksha A Mohiyiddeen Gadha G Ahmad Gaity G Fitzgerald Cheryl C Watson Andrew A Mohiyiddeen Lamiya L

The Cochrane database of systematic reviews 20211122

<h4>Background</h4>In an effort to improve outcomes of in vitro fertilisation (IVF) cycles, the use of growth hormone (GH) has been considered as adjuvant treatment in ovarian stimulation. Improving the outcomes of IVF is especially important for women with infertility who are considered 'poor responders'. We have compared the outcomes of IVF with adjuvant GH versus no adjuvant treatment in routine use, and specifically in poor responders.<h4>Objectives</h4>To assess the effectiveness and safety ...[more]

PMID: 34808697

Similar Datasets

Project description:IntroductionInfertility and in vitro fertilisation (IVF; with or without intracytoplasmic sperm injection) result in considerable emotional and financial burden. Increasing evidence suggests that lifestyle factors, including diet, physical activity and personal well-being, are associated with IVF-success rates. Currently, IVF is not routinely combined with a lifestyle programme. The preconception lifestyle (PreLiFe) randomised controlled trial (RCT) assesses the effects of a new mobile PreLiFe programme in couples undergoing IVF.Methods and analysisA multicentre RCT including 460 heterosexual couples starting IVF in Belgian fertility clinics. IVF couples are randomised between an attention control group or the PreLiFe programme for a period of 12 months or until an ongoing pregnancy is confirmed by ultrasound. The attention control programme includes a mobile application with treatment information (ie, appointments and medication instructions) in addition to standard care. The PreLiFe programme includes a mobile application with the same treatment information in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet, physical activity and mindfulness in combination with text messages and telephone interaction with a healthcare professional trained in motivational interviewing. The primary outcome of this RCT is the cumulative ongoing pregnancy rate within 12 months after randomisation. Secondary outcomes include changes in diet, physical activity, emotional distress, body mass index, waist circumference, quality of life and other reproductive outcomes including IVF discontinuation, clinical pregnancy rate and time to pregnancy. Additionally, partner support and the feasibility (use and acceptability) of the PreLiFe programme will be evaluated in the intervention group. Analysis will be according to intention to treat.Ethics and disseminationThis study has been approved by the Medical Ethical Committee of the Leuven University Hospital (Belgium) and the other recruiting clinics. The findings of this RCT will be disseminated through presentations at international scientific meetings and peer-reviewed publications.Trial registration numberNCT03790449; Pre-results.

Dataset Information

Growth hormone for in vitro fertilisation (IVF).

Publications

Growth hormone for in vitro fertilisation (IVF).

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets